A Phase 3, Multi-center, Multi-national, Placebo-controlled, Randomized, Double-blind 26 Week Study to Assess the Safety and Efficacy of CaPre® in Patients With Severe Hypertriglyceridemia

Trial Profile

A Phase 3, Multi-center, Multi-national, Placebo-controlled, Randomized, Double-blind 26 Week Study to Assess the Safety and Efficacy of CaPre® in Patients With Severe Hypertriglyceridemia

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Omega-3 phospholipid (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Acasti Pharma
  • Most Recent Events

    • 13 Nov 2017 According to an Acasti Pharma media release, phase 3 program is anticipated to complete in 2019.
    • 07 Nov 2017 According to an Acasti Pharma media release, Dariush Mozaffarian will be principal investigator of the phase 3 program. Acasti remains on track to begin activating sites for its Phase 3 program before the end of the year, with patient dosing expected to start in early 2018.
    • 30 Mar 2017 Data from this and another phase III trial (CT profile 283403) will support the New Drug Application (NDA) for CaPre for the treatment of hypertriglyceridemia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top